CG Oncology (NASDAQ:CGON) Sets New 12-Month High on Analyst Upgrade

CG Oncology, Inc. (NASDAQ:CGON)’s share price hit a new 52-week high on Tuesday after HC Wainwright raised their price target on the stock from $80.00 to $100.00. HC Wainwright currently has a buy rating on the stock. CG Oncology traded as high as $69.48 and last traded at $68.88, with a volume of 691604 shares changing hands. The stock had previously closed at $67.55.

A number of other research analysts have also weighed in on the company. Morgan Stanley set a $93.00 price objective on CG Oncology in a research report on Friday, January 9th. Royal Bank Of Canada raised their price objective on CG Oncology from $61.00 to $73.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st. Wall Street Zen lowered CG Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a research report on Wednesday, January 21st. Finally, Wedbush started coverage on CG Oncology in a research report on Thursday, December 11th. They set an “outperform” rating and a $70.00 price objective for the company. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $70.67.

Insider Activity at CG Oncology

In related news, Director James Mulay sold 11,145 shares of the stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $52.47, for a total value of $584,778.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 7.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CGON. AQR Capital Management LLC bought a new position in shares of CG Oncology in the 1st quarter valued at about $475,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of CG Oncology by 18.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,522 shares of the company’s stock valued at $876,000 after acquiring an additional 5,442 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of CG Oncology by 139.4% in the 1st quarter. Millennium Management LLC now owns 596,056 shares of the company’s stock valued at $14,597,000 after acquiring an additional 347,055 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of CG Oncology by 42.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 179,363 shares of the company’s stock valued at $4,393,000 after acquiring an additional 53,461 shares during the last quarter. Finally, Legal & General Group Plc lifted its holdings in shares of CG Oncology by 12.3% in the 2nd quarter. Legal & General Group Plc now owns 44,354 shares of the company’s stock valued at $1,153,000 after acquiring an additional 4,847 shares during the last quarter. Institutional investors own 26.56% of the company’s stock.

CG Oncology Stock Performance

The stock’s fifty day moving average is $59.73 and its 200 day moving average is $48.88. The stock has a market cap of $5.89 billion, a P/E ratio of -33.72 and a beta of 0.70.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings results on Friday, February 27th. The company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.10. The business had revenue of $2.32 million during the quarter. Equities research analysts predict that CG Oncology, Inc. will post -1.31 EPS for the current year.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.